Furosemide Tablets
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
SPE2D2-22-D-0140 P00008 to exercise Option Year 4 effective December 08, 2025 through December 07, 2026.
SPE2D2-22-D-0140 P00007 is modified in accordance with DoD Class Deviation 2025-O0003.
SPE2D2-22-D-0140 P00006 to exercise Option Year 3 effective December 08, 2024 through December 07, 2025.
SPE2D2-22-D-0140 P00005 is issued to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders into subject solicitation.
SPE2D2-22-D-0140 P00004 to exercise Option Year 2 effective December 08, 2023 through December 07, 2024.
SPE2D2-22-D-0140 P00003 to incorporate Drug Supply Chain Act (DSCA) language into solicitation for subject contract.
SPE2D2-22-D-0140 P00002 to Incorporate FAR 52.204-27 Prohibituion on a Bytedance Covered Application (June 2023) into contract.
Invocation of Option Year 1 Modification P00001 SPE2D2-22-D-0140
Contract Award for Furosemide Tablets SPE2D222D0140